AMB-066 / AmMax - LARVOL DELTA

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease (GlobeNewswire) - "AmMax Bio, Inc...announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer (CRC) and minimal residual disease (MRD) as well as those with MRD in other solid tumors. Under the agreements, AmMax and MD Anderson will build upon preclinical discoveries made by MD Anderson researchers to evaluate the potential for AMB-066, which targets colony stimulating factor 1 receptor (CSF1R), in a Phase 2a proof-of-concept study, with patient enrollment anticipated to begin soon."

Licensing / partnership • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase (GlobeNewswire) - "AmMax Bio, Inc...announced that it will present at the Oppenheimer Healthcare Private Company Showcase in New York City on Tuesday, October 1, 2024. Andrew Sauter, Chief Financial Officer, will present a company overview at 2:25 pm ET and will be available for 1x1 investor meetings, which can be requested through Oppenheimer....The Company’s AMB-066 program is on track to initiate enrollment in a phase 2 proof of concept study in the fourth quarter to treat patients with colorectal cancer with minimal residual disease (CRC MRD)."

New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor